

The Weekly

July 01, 2024





DOMESTIC INDICES			
	21-06-2024	28-06-2024	% CHG
SENSEX	77210	79033	2.4%
NIFTY	23501	24011	2.2%
MIDCAP	55429	55737	0.6%
SMALL CAP	18235	18318	0.5%

NIFTY EARNINGS			
NIFTY	FY 23	FY 24E	FY 25E
EPS	807	1000	1130
P/E	23	28	32

SECTORAL INDICES			
	21-06-2024	28-06-2024	% CHG
TECK	16760	17164	2.4%
IT	36173	36951	2.2%
OIL & GAS	28863	29473	2.1%
POWER	7816	7955	1.8%
BANKEX	58697	59641	1.6%
FMCG	20326	20550	1.1%
AUTO	56742	57293	1.0%
HEALTHCARE	36773	37110	0.9%
CG	71779	72324	0.8%
PSU	21104	21204	0.5%
CD	58769	58827	0.1%
METAL	33736	33051	-2.0%
REALTY	8843	8635	-2.4%

GLOBAL INDICES			
	21-06-2024	28-06-2024	% CHG
NIKKEI	38596	39687	2.8%
DAX	18164	18235	0.4%
NASDAQ	17689	17733	0.2%
S&P 500	5465	5460	-0.1%
DOW JONES	39150	39119	-0.1%
FTSE	8238	8164	-0.9%
SHANGHAI	2998	2970	-0.9%
HANG SENG	18029	17719	-1.7%
CAC	7629	7479	-2.0%

INSTITUTIONAL ACTIVITY			
Rs Cr	27-06-2024	28-06-2024	JULY TOTAL
FII	7659	-23	-23
DII	-3606	6658	6658

Indian markets could open flat, in line with muted Asian markets today and lower US markets on June 28

Stocks ended lower on Wall Street on Friday, erasing the S&P 500's gains for the week. The S&P 500 slipped 0.4% Friday, but remains close to the record high it set last week. The Nasdaq composite fell 0.7% and the Dow slipped 0.1%. U.S. stocks slipped Friday as traders digested fresh economic data that indicated slowing inflation, as well as better-than-expected consumer sentiment figures. An early rally fizzled as investors digested in-line inflation data and weighed political uncertainty after the U.S. presidential debate.

Traders are rearranging their positions in the aftermath of the debate between Joe Biden and Donald Trump. Biden's shaky performance boosted sentiment around Trump's odds for securing a second term in the White House. Private prisons, oil and health-insurance firms — some of the groups that would potentially win from another Trump presidency — rallied, while renewable energy and pot stocks sank. Treasury curve-steepening also followed the presidential debate.

The University of Michigan consumer sentiment index for June came in higher than expected, rising to 68.2 from the preliminary 65.6 reading. The one-year inflation outlook fell to 3% from 3.3% expected in May. Consumers were slightly more optimistic about the economy at the end of June, but the effects of high inflation in the past few years still weighed on their minds.

The core personal consumption expenditures price index in the US increased just a seasonally adjusted 0.1% for the month and was up 2.6% from a year ago the latter number down 0.2 percentage point from the April level. Both numbers were in line with the Dow Jones estimates. May marked the lowest annual rate since March 2021, which was the first time in this economic cycle that inflation topped the Fed's 2% target.

India's core sector growth eased to 6.3% in May, against the revised figure of 6.7% for the previous month, due to further contraction in the cement industry even as coal and electricity recorded higher output. This is the fifth consecutive month of contraction for fertilisers and second for cement. The crude oil sector also contracted in May after recording positive growth for four months.



LARGE CAPS (\$1B)

Price Performance

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Garden Reach Shipbuilders	2099.1	27.66	53.29
India Cements Ltd	293.57	26.71	43.56
Bombay Burmah Trading	2025.5	20.29	38.01
Tbo Tek Ltd	1902.9	19.82	35.15
Route Mobile Ltd	1823.4	19.19	23.49

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Creditaccess Grameen Ltd	1322.1	-10.22	-0.13
Happiest Minds Techno	817.3	-9.81	3.65
Motilal Oswal Financial	614.55	-9.13	10.74
Ce Info Systems Ltd	2301.25	-9.1	20
Nmdc Ltd	246.05	-8.77	-5.42

MID CAPS (\$1B - \$250M)

Price Performance

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Black Box Ltd	350.59	33.72	42.92
John Cockerill India Ltd	5998.15	31.76	64.82
Kalyani Investment Co Ltd	6298.45	27.52	42.24
Gtl Infrastructure Ltd	3.26	26.36	117.33
Pilani Investments & indus	5036.5	25.81	36.97

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Premier Explosives Ltd	746.55	-16.25	47.79
Arman Financial Services	2088.85	-14.98	4.13
Tips Industries Ltd	408.3	-12.52	-2.1
Fino Payments Bank Ltd	293.55	-10.96	7.88
Sh Kelkar & Co Ltd	185.45	-10.69	-3.71

SMALL CAPS (\$250M - \$100M)

Price Performance

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Yamuna Syndicate Ltd	350.59	71.37	101.61
Jindal Photo Ltd	5998.15	32.1	32.21
Digispice Technologies Ltd	6298.45	28.91	64.16
Borosil Scientific Ltd	3.26	28.23	-
Zodiac Energy Ltd	5036.5	27.62	14.17

Top 5 Gainers

Name	CMP	1 Week (%)	1 Month(%)
Vashu Bhagnani Industries	746.55	-22.6	17.9
Wardwizard Innovations	2088.85	-19.43	6.57
Amic Forging Ltd	408.3	-13.15	54.78
Newtime Infrastructure Ltd	293.55	-12.89	-11.31
Kesar India Ltd	185.45	-11.63	28.2

The Union government's fiscal deficit was curtailed to 3% of the budgetary target at the end of the first two months of the financial year-ending March 2025. The gap between expenditure and revenue during April-May stood at Rs 50,615 crore of the total limit set at Rs 16.85 lakh crore for the ongoing fiscal. The fiscal deficit figure follows a sharp contraction of Rs 1.59 lakh crore in May, owing to the surplus Reserve Bank of India dividend, reducing the deficit from Rs 2.1 lakh crore at the end of April.

India's rupee rose slightly, while government bonds were unable to gain meaningfully on the day of the much-awaited inclusion of the country's sovereign debt into a widely-tracked JPMorgan debt index as inflows underwhelmed investors. The benchmark bond yield was marginally higher at 7.01%. Foreign exchange market indicators had pointed to inflows, likely due to passive funds buying bonds, but multiple market participants said the quantum of inflows was sharply lower than anticipated. Traders had been betting on inflows of up to \$2 billion spread over Thursday and Friday.

Focus in the coming week will be on comments from Fed officials, chiefly Chairman Jerome Powell, who is set to speak at the European Central Bank's annual forum in Portugal on Tuesday, the minutes of the Fed's June meeting are also due on Wednesday, and also on key nonfarm payrolls data for June, due on Friday.

China released its official PMI figures on the weekend, with its manufacturing PMI coming in at 49.5, unchanged from May and marking its second straight month in contraction territory. A private survey of manufacturing activity, however, diverged from the official numbers, showing the sharpest improvement in business conditions in three years. The S&P Caixin PMI climbed to 51.8 in June compared with 51.7 in May and 51.2 forecast.

Asia-Pacific markets started the second half of the year mixed as investors assessed June business activity data from China as well as Japan's business confidence readings.



Nifty ended slightly lower on June 28 forming a minor bearish pattern. However, on weekly charts, Nifty rose for the fourth consecutive week (up 2.17% - the largest weekly gain in 5 months) to record its best month so far this year. On weekly charts, the Nifty formed a large bull candle breaking out of a range. On monthly charts, Nifty gained 6.57% - the largest monthly gain in 6 months. Nifty could face resistance from the 24174-24380 band while support could come in at 23338 in the near term. Nifty keeps defying all expectations of giving even a small correction.

Gail advances its net zero emissions target by five years

GAIL (India) Ltd, has advanced its target for completely eliminating carbon emissions by five years to 2035. GAIL plans to achieve this by adopting various approaches including electrification of its processes and using renewable energy, battery energy storage systems, compressed biogas, green hydrogen, and afforestation.

Vodafone Idea to raise mobile tariff by 10% to 24%, following moves by Reliance Jio and Bharti Airtel

Vodafone Idea will revise its mobile service tariffs by around 10% to 24% after Jio and Airtel hiked them in the first week of July. Vodafone Idea (Vi) announces that mobile tariffs will be raised on July 4th.

DoT to issue demand note to Airtel, Vodafone Idea and Jio this week for payment

The telecom department is expected to issue a demand note to telcos this week for payment of spectrum they bought in the just-concluded auction, according to a source. The auction -- lasted for two days spanning seven rounds this time around - witnessed the sale of 141.4 MHz of radio waves for Rs 11,340.78 crore.

GAIL says Urja Ganga gas pipeline completion delayed to March 2025

The construction of the Rs 12,940-crore 'Urja Ganga' gas pipeline, India's most ambitious project taking environment-friendly fuel to eastern parts of the country, has been delayed by nine months and will now be completed by March 2025, state-owned GAIL (India) Ltd said. The 3,306-kilometre Jagdishpur-Haldia-Bokaro-Dhamra pipeline was originally targeted for completion by June 2024.

Recovery in rural markets, improving employment conditions bodes well for near-term consumption: ITC

The Indian economy is expected to sustain its "high growth" trajectory in the current fiscal, driven by strong momentum in infrastructure investments and a pickup in private consumption, ITC Ltd said.

Growth will come on the back of a moderation in inflation, improvement in agricultural trade, a good rabi harvest and a normal monsoon, the hotels-to-packaged consumer goods company said in its annual report for FY24, released on Friday.

The company pointed to "green shoots" of recovery in the rural markets, improving employment conditions and a sustained momentum in manufacturing and services that it said augur well for consumption demand in the near term.

Poly Medicare board approved to raise up to Rs 1000 crore through QIP

Board approved to raise fund up to Rs 1000 crore through qualified institutional placement (QIP). It would be subject to shareholders' approval and receipt of regulatory approvals.

Epigral Ltd. commissioned CPVC compound facility at Dahej

Company had informed about to set-up Chlorinated Polyvinyl Chloride (CPVC) Compound manufacturing plant at its Dahej facility at Gujarat. Company has successfully commissioned 35,000 TPA (Tonnes Per Annum) capacity of CPVC Compound plant at its Dahej facility in Gujarat.



Orchid Pharma partners with Cipla to launch anti-biotic Cefepime Enmetazobactam in India

Orchid Pharma Limited announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a collaboration, Orchid Pharma has partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. The launch marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India's leadership in medical innovation.

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible.

Wockhardt announced successful use of Investigational Anti-biotic, Zaynich (Zidebactam/Cefepime-WCK 5222) to treat a cancer patient in US with Chronic Bilateral Thigh Infection

A young immune-compromised cancer patient, who has been hospitalized for nearly 9 months at Children's Hospital of Orange County, University of California Irvine School of Medicine was successfully treated with 4 weeks of Zaynich (WCK 5222) for chronic thigh infection under compassionate use, enabling doctors to resume chemotherapy. During the long hospital stay, patient grappled with multiple rounds of infections necessitating extensive use of several antibiotics. With no treatment options left, the hospital sought the access to Zaynich (Zidebactam/Cefepime- WCK 5222) under a provision termed as 'Expanded Access IND' granted by the US FDA. This case marks the first instance in the US where Zaynich (Zidebactam/Cefepime- WCK 5222) has been employed to combat a complex infection caused by extreme-drug resistant Pseudomonas.

Update on enhancement of capacity of Bio-Fuel Ethanol plant (Ethanol to Bio-Fuel conversion)

India Glycols said that this is further to intimations dated 2nd February and 7th March, 2024 in connection with the enhancement of capacity of Bio-Fuel Ethanol plant at Kashipur (Uttarakhand). As an update, the second phase of expansion (180 KLPD) of Bio-Fuel Ethanol plant (Ethanol to Bio-Fuel conversion) at Kashipur is in progress and is expected to be commissioned by Q2FY25.

Blue Jet Healthcare commissioned multi- product Production block at Ambernath (Unit II)

Blue Jet Healthcare Limited at the Company's existing Unit 2 facility situated at Ambernath, Maharashtra, India, has successfully commissioned multi-product Production block to manufacture pharma intermediates and have commenced manufacturing of Validation Batches w.e.f 29th June 2024.

Company propose to commercialize full scale production within next six months. It has incurred a capex of Rs 90 crore in the same.

Neogen Chemicals promoter divests 5.6% stake

Neogen Chemicals promoter Haridas Kanani has divested a 5.67% stake of the company. Even after the stake sale, the promoter continues to retain majority ownership in Neogen Chemicals, the company said in a filing on June 29. The stake was acquired by existing long-standing institutional investors like SBI Mutual Fund and White Oak Group.

The proceeds from this transaction will be utilised by the promoter for taking care of his and his family's long term financial plans and goals, the company said.

Tata Steel to convert \$565 million debt into equity in subsidiary T Steel Holdings

Tata Steel Ltd on Friday (June 28) said has announced the conversion of debt instruments valued at \$565 million (Rs 4,713.03 crore) into equity shares in its wholly owned subsidiary, T Steel Holdings Pte. Ltd. (TSHP). This follows the approval granted by Tata Steel's Board of Directors on May 29, 2024, to convert debt instruments held by the company in TSHP during the fiscal year 2024-25.



Godrej Properties acquires 11-acre land parcel in Pune with Rs 1,800 crore revenue potential

Godrej Properties Ltd on Friday (June 28) said the company has acquired leasehold rights for an 11-acre land parcel in Hinjewadi, Pune. This acquisition offers a developable potential of 2.2 million square feet, with an estimated revenue potential of Rs 1,800 crore.

Ginger Hotels looks to double footprint in East, Northeast in 3-5 years

Tata Group's budget hospitality brand Ginger Hotels is looking to double its presence in East and Northeast India in the next three to five years, according to a senior company official. Ginger Hotels, operated by Roots Corporation Ltd (RCL), a subsidiary of the Indian Hotels Company (IHCL), has 11 properties in operation with 876 rooms in the East and Northeast region and seven in the pipeline with an expected 605 rooms to be added. The brand is seeking to tap growth witnessed in India beyond the metros to smaller cities.

Mumbai clocks 12% growth in property registrations in June: Knight Frank

The registration of properties in the Mumbai municipal region rose 12 per cent annually in June to 11,575 units on better demand for housing assets, according to Knight Frank. Mumbai city (area under Bombay Municipal Corporation jurisdiction) saw registration of 11,575 units in June against 10,319 units in the same month last year, as per the data compiled by real estate consultant Knight Frank from the Maharashtra government portal. However, the number of registrations in June was lower than in May, when 12,000 units were registered.

Zydus and Dr Reddy's ink licensing agreement to co-market Pertuzumab in India

Zydus Lifesciences and Dr. Reddy's Laboratories announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India. Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC).

Under the terms of this agreement, Dr. Reddy's will receive semi-exclusive rights from Zydus to co-market the product in India. The product will be marketed by Zydus under the brand name Sigrima. Dr. Reddy's will market it under the brand name Womab. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones.

JSW Neo Energy Gets LoA For 300 MW Wind-Solar Hybrid Power Projects From SJVN

JSW Neo Energy Ltd., a wholly owned subsidiary of the power producer JSW Energy, has received a Letter of Award for wind-solar hybrid power projects of 300 megawatts capacity from SJVN Ltd., it said in an exchange filing.

SJVN Ltd. had invited companies to set up 1,500 MW interstate transmission system connected wind-solar hybrid power projects via tariff-based competitive bidding. This increases JSW Energy's total locked-in capacity to 13.9 GW, a statement said. "The company expects to have an installed generation capacity of 9.8 GW by 2024, up from 7.3 GW currently.



Key Events

U.S. inflation slows as expected in May

Inflation in the U.S. decelerated as expected in May on an annualized basis, according to the Federal Reserve's preferred measure of price gains, potentially providing more impetus for the Fed to roll out interest rate cuts in 2024.

In the 12 months to May, the headline personal consumption expenditures price index cooled to 2.6% from 2.7%. The figure came in at 0.0% on a monthly basis following a rise of 0.3% in April -- the first time the number did not increase in half a year.

China's June factory activity contracts again, services slows

China's manufacturing activity fell for a second month in June while services activity slipped to a five-month low, an official survey showed on Sunday, keeping alive calls for further stimulus as the economy struggles to get back on its feet.

The National Bureau of Statistics (NBS) purchasing managers' index (PMI), at 49.5 in June, was unchanged from May, below the 50-mark separating growth from contraction and in line with a median forecast of 49.5 in a Reuters poll.



Index	CMP	View	R1	R2	S1	S2
Nifty July Future	24132	Positive	24250	24365	24020	23850
Bank Nifty July Future	52529	Consolidation	52950	53520	52090	51650

Daily Technical View on Nifty

Buy on dips opportunity..

Observation: After showing consistent upmove in the last four sessions, Nifty slipped into minor profit booking from the new highs on Friday and closed the day lower by 33 points. All time high was registered at 24174.

A small negative candle was formed on the daily chart on Friday with small upper shadow. Technically, this formation indicates consolidation or chances of minor dip in the market from the highs.

Further weakness from here is expected to be a buying opportunity at the lower supports. However, a sustainable move above 24200 levels is likely to resume decisive upside momentum for the near term.

Nifty on the weekly chart formed a long bull candle after a consolidation of last two weeks. This upside breakout is likely to have more positive impact in coming week.

Conclusion: The underlying trend of Nifty from smaller to larger timeframe remains up. Though market placed at the highs, still there is no confirmation of any significant reversal pattern building at the new highs.

Having placed at the minor hurdle, there is a possibility consolidation or minor dips in the intra-month and that is expected to be a buying opportunity. Immediate support is placed at 23650 levels.

The upside targets to be watched around 24380 (1.618% Fibonacci Extension) and 24960 (1.786% Fibonacci Extension) in the next 1-2 months.





OPEN SHORT TERM TRADING CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET	UPSIDE %	VALID TILL
1	26-JUN-24	BUY	FEDERAL BANK JULY FUT	179.50-174	178.8	171.0	191	6.8	1-JUL-24
2	21-JUN-24	BUY	IRCON	279-269	269.7	265.0	299	10.9	5-JUL-24
3	27-JUN-24	BUY	ANTONY WASTE	508-490	511.5	482.0	550	7.5	11-JUL-24
4	28-JUN-24	BUY	SBI	846-858.15	849.0	836.0	890	4.8	12-JUL-24

OPEN E-MARGIN POSITIONAL CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET 1	TARGET 2	UPSIDE %	VALID TILL
1	10-JUN-24	BUY	REDINGTON	206-212	214.2	199.0	235.0	250.0	17	10-SEP-24
2	11-JUN-24	BUY	IFCI	60.98-56.50	61.6	54.0	68.0	72.0	17	11-SEP-24
3	11-JUN-24	BUY	ZENSAR TECHNOLOGY*	691.25-647	747.4	691.3	762.0	795.0	6	11-SEP-24
4	11-JUN-24	BUY	AARTI INDUSTRIES*	640-663.30	686.3	663.3	712.0	760.0	11	11-AUG-24
5	13-JUN-24	BUY	KOPRAN	247.30-235	253.4	228.0	270.0	300.0	18	13-SEP-24
6	14-JUN-24	BUY	BEML*	4100-4260.6	4438.1	4260.6	4641.0	5000.0	13	14-SEP-24
7	14-JUN-24	BUY	STAR	947-890	948.9	870.0	1045.0	1090.0	15	14-SEP-24
8	18-JUN-24	BUY	DATA PATTERNS	2985.10-2835	3001.4	2745.0	3265.0	3450.0	15	18-SEP-24
9	18-JUN-24	BUY	PRICOL	482.45-464	492.1	450.0	527.0	555.0	13	18-SEP-24
10	19-JUN-24	BUY	IDFC FIRST BANK	82.65-79.50	82.2	77.5	89.0	97.0	18	19-AUG-24

*= 1st Target Achieved



OPEN FUNDAMENTAL CALLS

Time Horizon= 2 - 3 Quarters

NO.	COMPANY NAME	RECO DATE	CMP	BUYING RANGE	TARGET 1	TARGET 2	UPSIDE %
1	SHARDACROP	3-Jul-23	446.5	554-560	606.5	645.5	44.57
2	PSPPROJECT	7-Aug-23	685.7	772-788	850	908	32.42
3	ZYDUSWELL	24-Aug-23	1786	1580-1600	1735	1905	6.66
4	MANYAVAR*	23-Oct-23	1051.65	1300-1325	1445	1555	47.86
5	SDBL*	6-Nov-23	114	128-131.2	142.8	154.8	35.79
6	AUTOAXLES	13-Nov-23	2000.4	2330-2375	2548	2758	37.87
7	JYOTIRES	16-Nov-23	1423	1621-1650	1806	1936	36.05
8	CRAFTSMAN*	22-Nov-23	5541.55	5060-5160	5580	5965	7.64
9	IOLCP*	28-Nov-23	403.65	452-458	496.5	543.5	34.65
10	CSBBANK*	4-Dec-23	378.15	380-388	417	456	20.59
11	ADVENZYMES*	18-Dec-23	381.75	369-373	407.5	436	14.21
12	DATAMATICS*	22-Dec-23	619.3	701-715	782	829	33.86
13	ANDHRAPAP	26-Dec-23	567.75	590-597	649	721	26.99
14	JTLIND	11-Jan-24	222.57	252-261	278.75	300.5	35.01
15	MUNJALAU	15-Jan-24	88.85	104-106	116	125	40.69
16	GRANULES*	16-Jan-24	492.8	430-434	470.5	507	2.88
17	JAYBARMARU	23-Jan-24	108.99	134-137	150	161	47.72
18	SHREDIGCEM	23-Jan-24	111.41	116-120	129	144.5	29.70
19	SATIN	29-Jan-24	220.46	251-257	279	303	37.44
20	NH	5-Feb-24	1204.75	1342-1358	1467	1557	29.24
21	L&TFH*	5-Feb-24	181.17	173-177	190	206	13.71
22	CYIENTDLM*	12-Feb-24	747.25	768-784	845	905	21.11
23	MARKSANS*	26-Feb-24	159.04	158-161	175	187.25	17.74
24	BIRLACORPN	27-Feb-24	1597.05	1725-1760	1891	1996	24.98
25	CRISIL	4-Mar-24	4251.9	4900-5000	5414	5821	36.90
26	FDC	4-Mar-24	462.05	446-452	491.5	529.5	14.60
27	CYIENT	3-Apr-24	1837	1989-2029	2191	2340	27.38
28	ECLERX	4-Apr-24	2419.1	2426-2476	2685	2830	16.99
29	SHK	22-Apr-24	185.45	202-206	223.5	241.5	30.22
30	MAHLIFE	22-Apr-24	596.65	615-625	684	725	21.51
31	SUBROS*	25-Apr-24	647.35	600-615	662	715	10.45
32	UBL	29-Apr-24	1986.05	2030-2050	2245	2401	20.89
33	MCDOWELL-N*	6-May-24	1276.5	1190-1210	1319	1386	8.58

*= 1st Target Achieved



OPEN FUNDAMENTAL CALLS

Time Horizon= 2 - 3 Quarters

NO.	COMPANY NAME	RECO DATE	CMP	BUYING RANGE	TARGET 1	TARGET 2	UPSIDE %
34	COALINDIA	6-MAY-24	473.15	468-478	536	-	13.28
35	ALLSEC*	21-MAY-24	1154.05	1043-1065	1162	1261	9.27
36	MAHINDCIE*	24-MAY-24	572.3	536-548	588	629	9.91
37	GLAXO*	24-MAY-24	2651	2470-2498	2704	2889	8.98
38	VSTIND*	27-MAY-24	3995.35	3980-4000	4411	4710	17.89
39	MMFL*	27-MAY-24	1237.75	1120-1145	1240	1344	8.58
40	HCLTECH	10-JUN-24	1440.5	1415-1445	1650	-	14.54
41	SUPRAJIT	12-JUN-24	510.85	485-495	540	580	13.54
42	JKIL	18-JUN-24	830.75	813-829	902	976	17.48
43	GLENMARK	18-JUN-24	1230.5	1230-1252	1366.5	1478.5	20.15
44	UTIAMC	18-JUN-24	1000.5	995-1015	1100	1180	17.94
45	INDNIPPON	18-JUN-24	811.25	785-800	863	932	14.88

*= 1st Target Achieved



Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.



HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.